Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2026 · third_quarter · Q3
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Source: Senate LDA
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Department of State Policy Provisions Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2027 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
Department of State Policy Provisions Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2027 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
Department of State Policy Provisions Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2027 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period, including S.1717 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Corporate Tax and Tariffs, H.R.1 - One Big Beautiful Bill Act
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics
Diagnostics Testing Preparedness Plan Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Department of State Policy Provisions Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2026 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
Department of State Policy Provisions Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2026 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period, including S.1717 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Corporate Tax and Tariffs, H.R.1 - One Big Beautiful Bill Act
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
RESULTS Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act) FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
VALID Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act) FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. Issues related to the regulation of diagnostics
State Strategic Stockpile Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act) FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. Issues related to the regulation of diagnostics
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
Protecting America from Seasonal and Pandemic Influenza Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Protecting America from Seasonal and Pandemic Influenza Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Protecting America from Seasonal and Pandemic Influenza Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act) FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Protecting America from Seasonal and Pandemic Influenza Act of 2023
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Saving Access to Laboratory Services Act
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
National Defense Authorization Act for Fiscal Year 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Sec. 828 of S.4638, the National Defense Authorization Act for Fiscal Year 2025, Right to Repair
National Defense Authorization Act for Fiscal Year 2025
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
Sec. 828 of S.4638, the National Defense Authorization Act for Fiscal Year 2025, Right to Repair
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
Client: F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES · Firm: F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period.
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2027 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2026 · second_quarter · Q2
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2027 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Breast and Cervical Cancer, Alzheimer's and Influenza Preparedness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2026 · first_quarter · Q1
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness Clinical Lab Fee Schedule reform, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act H.R. 5269 / S. 2761 and Medicare coverage of FDA approved breakthrough diagnostics, S.1717 / H.R. 5343 The Ensuring Patient Access to Critical Breakthrough
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2027 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period. Issues related to Tariffs and Department of Commerce 232 investigation on Medical Technologies FY2027 Appropriations for Labor, Health and Human Services, Education, and Related Agencies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2025 · fourth_quarter · Q4
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2026 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2025 · third_quarter · Q3
Access to and reimbursement of diagnostics in the Medicare program. H.R. 5269 / S. 2761 Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. S.1717 / H.R.5343 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period Issues related to Tariffs
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2026 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization (H.R.5300 - Department of State Policy Provisions Act)
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2025 · second_quarter · Q2
Access to and reimbursement of diagnostics in the Medicare program. Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period, including S.1717 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Corporate Tax and Tariffs, H.R.1 - One Big Beautiful Bill Act
(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2026 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2025 · first_quarter · Q1
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2024 · fourth_quarter · Q4
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and S. 5349/ H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023. Issues related to the coverage of neurology markers on the Clinical Lab Fee Schedule
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2024 · third_quarter · Q3
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Sec. 828 of S.4638, the National Defense Authorization Act for Fiscal Year 2025, Right to Repair
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2024 · second_quarter · Q2
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
FOR: Support authorization and appropriations for President's Emergency Plan for AIDS Relief (PEPFAR)
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act) FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2024 · first_quarter · Q1
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2023 · fourth_quarter · Q4
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), and H. R. 5846 Protecting America from Seasonal and Pandemic Influenza Act of 2023 (the Influenza Act)
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2023 · third_quarter · Q3
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, H. R. 1305 Saving Us from Pandemic Era Resistance by Building a Unified Global Strategy Act of 2023", Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act, H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H.R.3723 Medical Device Electronic Labeling Act, and influenza preparedness
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2023 · second_quarter · Q2
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act, H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H.R.3723 Medical Device Electronic Labeling Act, and influenza preparedness
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2023 · first_quarter · Q1
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA)
(MED) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act
HCR: The Verifying Accurate Leading-edge IVCT Development Act and Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2022 · fourth_quarter · Q4
MED: H.R. 2617 Consolidated Appropriations Act, 2023, H.R. 4128/S. 2209, The Verifying Accurate Leading-edge IVCT Development Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act and Pandemic All Hazards Preparedness Act Reauthorization
(MMM): H.R. 2617 Consolidated Appropriations Act, 2023, H.R. 4128/S. 2209 and Clinical Lab Fee Schedule S.4449 / HR 8188 Saving Access to Laboratory Services Act (SALSA)
HCR: H.R. 2617 Consolidated Appropriations Act, 2023, H.R. 4128/S. 2209, The Verifying Accurate Leading-edge IVCT Development Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act and Pandemic All Hazards Preparedness Act Reauthorization
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2022 · third_quarter · Q3
(MMM) Clinical Lab Fee Schedule S.4449 / HR 8188 Saving Access to Laboratory Services Act (SALSA)
(MED and HCR): S.4348 FDASLA Act of 2022/ H.R. 7667 Food and Drug Amendments of 2022, H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act, H.R. 6000 CURES Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act
(MED and HCR): S.4348 FDASLA Act of 2022/ H.R. 7667 Food and Drug Amendments of 2022, H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act, H.R. 6000 CURES Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2022 · second_quarter · Q2
(HCR): S.4348 FDASLA Act of 2022/ H.R. 7667 Food and Drug Amendments of 2022, H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act, H.R. 6000 CURES Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act
(MMM) Clinical Lab Fee Schedule S.4449 / HR 8188 Saving Access to Laboratory Services Act (SALSA)
(MED): S.4348 FDASLA Act of 2022/ H.R. 7667 Food and Drug Amendments of 2022, H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act, H.R. 6000 CURES Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2022 · first_quarter · Q1
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act, H.R. 6000 CURES Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act, H.R. 6000 CURES Act. Issues related to public health emergency preparedness, including S. 3799 PREVENT Pandemics Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2021 · fourth_quarter · Q4
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act Issues related to public health emergency preparedness
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act. Issues related to public health emergency preparedness
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2021 · third_quarter · Q3
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act. H.R. 747/S.1018 The Access to Technology and Equipment for Same-day Tests Act. H.R.1436/S. 308 Protecting Providers Everywhere in America Act. H.R. 3635/S. 1974 Strengthening America's Strategic National Stockpile Act H.R. 3463/S.1693 Medical Supplies for Pandemics Act. Build Back Better Reconciliation Package Issues related to public health emergency preparedness
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act. H.R. 747/S.1018 The Access to Technology and Equipment for Same-day Tests Act. H.R.1436/S. 308 Protecting Providers Everywhere in America Act. H.R. 3635/S. 1974 Strengthening America's Strategic National Stockpile Act H.R. 3463/S.1693 Medical Supplies for Pandemics Act. Build Back Better Reconciliation Package Issues related to public health emergency preparedness
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES via F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES
2021 · second_quarter · Q2
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act. H.R. 747/S.1018 The Access to Technology and Equipment for Same-day Tests Act. H.R.1436/S. 308 Protecting Providers Everywhere in America Act. H.R. 3635/S. 1974 Strengthening America's Strategic National Stockpile Act H.R. 3463/S.1693 Medical Supplies for Pandemics Act. Issues related to public health emergency preparedness
H.R. 4128/S. 2209 The Verifying Accurate Leading-edge IVCT Development Act. H.R. 747/S.1018 The Access to Technology and Equipment for Same-day Tests Act. H.R.1436/S. 308 Protecting Providers Everywhere in America Act. H.R. 3635/S. 1974 Strengthening America's Strategic National Stockpile Act H.R. 3463/S.1693 Medical Supplies for Pandemics Act. Issues related to public health emergency preparedness
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
(MMM) Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics (preeclampsia)
(FOR) PEPFAR Reauthorization / FY2026 Appropriations for PEPFAR laboratory services and testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. Issues related to the regulation of diagnostics
Sec. 828 of S.4638, the National Defense Authorization Act for Fiscal Year 2025, Right to Repair
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID)
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID)
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID)
(HCR) H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, SCREENS Act (HR 3916), issues related to 3rd party servicing of medical equipment (Right to Repair), H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office
H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act, H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act. (HCR) H. R. 1305 Saving Us from Pandemic Era Resistance by Building a Unified Global Strategy Act of 2023", and issues related to influenzas preparedness Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA)
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office
(MMM) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA), and HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act of 2023
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Medicare payment for clinical laboratories and diagnostic tests.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office